LncRNA-p21 suppresses cell proliferation and induces apoptosis in gastric cancer by sponging miR-514b-3p and up-regulating ARHGEF9 expression
Author:
Ma Xiaobin1, Yan Wenyu1, Xu Peng1, Ma Li1, Zan Ying1, Huang Lanxuan1, Wang Guanying1, Liu Lili1, Hui Wentao1ORCID
Affiliation:
1. Department of Oncology , The Second Affiliated Hospital of Medical School of Xi’an Jiaotong University , No. 157 Xiwu Road , Xi’an 710004 , Shaanxi , China
Abstract
Abstract
The long non-coding RNA p21 (lncRNA-p21) was a tumor suppressor gene in most cancer types including gastric cancer (GC). We aimed to identify a specific lncRNA-p21-involved pathway in regulating the proliferation and apoptosis of GC cells. A lower lncRNA-p21 expression in tumors was associated with advanced disease stage and predicted worse survival of GC patients. LncRNA-p21 overexpression in GC cell line somatic gastric cancer (SGC)-7901 and human gastric cancer (HGC)-27 suppressed cell proliferation and enhanced apoptosis, while lncRNA-p21 knockdown caused the opposite effects. Through bioinformatics analysis and luciferase-based reporter assays, we identified miR-514b-3p as a sponge target of lncRNA-p21. Cdc42 guanine nucleotide exchange factor 9 (ARHGEF9), functioned as a tumor suppress factor in GC, was found as the downstream target of miR-514-3p, and their expressions were negatively correlated in GC tumor tissues. In addition, like lncRNA-p21 overexpression alone, miR-514-3p inactivation alone also led to decreased proliferation and increased apoptosis in SGC-7901 and HGC-27 cells, which were markedly attenuated by additional ARHGEF9 knockdown. Xenograft SGC-7901 cells with more lncRNA-p21 or ARHGEF9 expressions or with less miR-514-3p expression exhibited obviously slower in vivo growth than the control SGC-7901 cells in nude mice. Our study reveals a novel lncRNA-p21/miR-514b-3p/ARHGEF9 pathway that can be targeted for GC therapy.
Publisher
Walter de Gruyter GmbH
Subject
Clinical Biochemistry,Molecular Biology,Biochemistry
Reference40 articles.
1. Alexander, S. and Friedl, P. (2012). Cancer invasion and resistance: interconnected processes of disease progression and therapy failure. Trends Mol. Med. 18: 13–26, https://doi.org/10.1016/j.molmed.2011.11.003. 2. Alsina, M., Miquel, J.M., Diez, M., Castro, S., and Tabernero, J. (2019). How I treat gastric adenocarcinoma. ESMO Open 4: e000521, https://doi.org/10.1136/esmoopen-2019-000521. 3. Ao, X., Jiang, M., Zhou, J., Liang, H., Xia, H., and Chen, G. (2019). lincRNAp21 inhibits the progression of nonsmall cell lung cancer via targeting miR175p. Oncol. Rep. 41: 789–800. 4. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68: 394–424, https://doi.org/10.3322/caac.21492. 5. Chen, S., Liang, H., Yang, H., Zhou, K., Xu, L., Liu, J., Lai, B., Song, L., Luo, H., Peng, J., et al.. (2017a). LincRNa-p21: function and mechanism in cancer. Med. Oncol. 34: 98, https://doi.org/10.1007/s12032-017-0959-5.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|